Margaret Juliana McElrath

Institution:

FRED HUTCHINSON CANCER RESEARCH CENTER

Email:

Awarded COVID Grants:

CoVPN 3002 A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222 for the Prevention of COVID-19 LAB

HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3

CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Lab

HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals: LC

SARS-CoV-2 testing at the Seattle Vaccine and Prevention CRS (30331)

Upgrading Institutional Capacity with a BSL-3 Facility for Multidisciplinary Biomedical Research

Back to Top